Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: PR Newswire
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer.Volition panelPSA alone94%33%At 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). This compares with just 33% identified by Prostate-Specific Antigen (PSA) alone."This is a very exciting outcome for us as we continue the development of our assays beyond colorectal cancer. The preliminary data from this study showed that Volition's panel of assays identified men with potentially lethal high-grade prostate cancer with much greater accuracy than PSA alone. Based on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech [Yahoo! Finance]Yahoo! Finance
- Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through AntechPR Newswire
- Antech's breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection [Yahoo! Finance]Yahoo! Finance
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Antech's Breakthrough AI-powered Radiology and Targeted Cancer Screening Tools Now Available, Unleashing New Chapter for Veterinary Diagnostics [Yahoo! Finance]Yahoo! Finance
VNRX
Earnings
- 11/14/23 - Beat
VNRX
Sec Filings
- 3/26/24 - Form D
- 3/25/24 - Form 10-K
- 3/25/24 - Form 8-K
- VNRX's page on the SEC website